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treated patients. Only reports of conjunctival hemorrhage 
(18.2 vs. 8.5%) and intraocular pressure elevation (13.2 vs. 
4.2%) were significantly different in the DEX versus the sham 
treatment groups.  Conclusion: DEX reduced the need for ad-
junctive ranibizumab treatment and showed acceptable tol-
erability in nvAMD patients.  © 2015 S. Karger AG, Basel 
 Introduction 
 Neovascular age-related macular degeneration 
(nvAMD), a common cause of legal blindness in individ-
uals over the age of 50  [1–4] , is characterized by choroidal 
neovascularization (CNV)  [5, 6] . CNV tissue consists of 
blood vessels, inflammatory cells, and mesenchymal cells 
within a loose extracellular matrix  [7] . Subretinal leakage, 
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 Abstract 
 Purpose: To evaluate the efficacy and safety of dexametha-
sone intravitreal implant 0.7 mg (DEX) as adjunctive therapy 
to ranibizumab in neovascular age-related macular degen-
eration (nvAMD).  Procedures: This was a 6-month, single-
masked, multicenter study. Patients were randomized to 
DEX implant (n = 123) or sham procedure (n = 120) and re-
ceived 2 protocol-mandated intravitreal ranibizumab injec-
tions. The main outcome measure was injection-free in-
terval to first as-needed ranibizumab injection.  Results: DEX 
increased the injection-free interval versus sham (50th per-
centile, 34 vs. 29 days; 75th percentile, 85 vs. 56 days; p = 
0.016). 8.3% of DEX versus 2.5% of sham-treated patients did 
not require rescue ranibizumab (p = 0.048). Visual acuity and 
retinal thickness outcomes were similar in DEX and sham-
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hemorrhage, and fluid accumulation can lead to rapid vi-
sion loss, but nonvascular components of the disease pro-
cess, such as inflammation and fibrosis, are also believed 
to contribute to disease progression  [8–10] . Inflamma-
tory involvement has been demonstrated in studies of ex-
cised CNV tissue of nvAMD patients. Growth of CNV 
into the subretinal pigment epithelium space may be aug-
mented by activated macrophages and other inflamma-
tory cells that secrete enzymes and cytokines that degrade 
Bruch’s membrane  [6] . 
 Vascular endothelial growth factor (VEGF) stimulates 
angiogenesis and vascular leakage and is believed to have 
a primary role in CNV associated with nvAMD. Anti-
VEGF agents are currently approved for first-line treat-
ment of CNV in nvAMD: pegaptanib (Macugen ® ; Vale-
ant Pharmaceuticals International Inc., Toronto, Ont., 
Canada), an aptamer to VEGF; ranibizumab (Lucentis ® ; 
Genentech Inc., South San Francisco, Calif., USA), a re-
combinant humanized Fab fragment of a murine mono-
clonal anti-VEGF antibody, and aflibercept (Eylea; Re-
generon Pharmaceuticals, Tarrytown, N.Y., USA), a re-
combinant fusion protein with binding domains from 
human VEGF receptors. However, outcomes are subop-
timal for many patients.
 A treatment approach that targets multiple compo-
nents of the disease process may effectively prevent pro-
gression and restore vision in nvAMD  [7, 8, 11–13] . One 
approach that has been used focuses on both angiogenesis 
and the underlying inflammatory factors. Although oral 
corticosteroids are potent anti-inflammatories, they are 
associated with severe systemic side effects  [14] . Intravit-
real injections of triamcinolone acetonide and dexameth-
asone have a more favorable safety profile and have been 
used off-label as adjunctive therapy to anti-VEGF agents 
and photodynamic therapy in the treatment of nvAMD 
 [15–19] . Corticosteroids inhibit the capillary dilation, 
leukocyte migration, and edema associated with inflam-
mation  [20] . They may also block the fibroblast activation 
and proliferation that leads to scarring  [21] . High-dose 
corticosteroid pulse dosing has been shown to cause 
apoptosis of cells involved in an inflammatory response, 
including peripheral T cells and eosinophils  [22–24] . In 
animal models, intravitreal corticosteroid injections have 
been shown to inhibit both VEGF production  [25] and 
CNV membrane development  [26] .
 Dexamethasone is approximately 5 times more potent 
than triamcinolone  [27] and has demonstrated less toxic-
ity in cultures of human retinal pigment epithelium cells 
 [28] and human lens epithelial cells  [29] . As dexametha-
sone is cleared rapidly (half-life <4 h) from the vitreous 
humor after a single intravitreal injection  [30–32] , an in-
travitreal biodegradable drug delivery system (Novadur ® ; 
Allergan Inc., Irvine, Calif., USA) allows controlled release 
of dexamethasone over an extended period  [33] . Dexa-
methasone intravitreal implant (DEX implant) 0.7 mg 
(Ozurdex ® ; Allergan) consists of a biodegradable copoly-
mer, polylactic- co -glycolic acid, that contains micronized 
dexamethasone, which is slowly released. A single-use ap-
plicator system is used to place DEX implant in the vitre-
ous through a 22-gauge needle  [34] . Shown to be safe and 
effective in phase 2 and 3 trials  [35, 36] , DEX implant was 
recently approved for use in the treatment of diabetic mac-
ular edema. DEX implant 0.7 mg is also approved for the 
treatment of branch and central retinal vein occlusion  [37–
40] , and for noninfectious uveitis that affects the posterior 
segment [ 41 , for a review see Herrero-Vanrell et al.  42 ]. 
 The purpose of this study was to evaluate the efficacy 
and safety of DEX implant 0.7 mg used as adjunctive 
 therapy to ranibizumab in patients with CNV secondary 
to nvAMD. Our clinical hypothesis was that adjunctive 
therapy with DEX implant would decrease or delay the 
need for retreatment with ranibizumab.
 Procedures 
 Study Design and Patients 
 This was a 6-month, randomized, multicenter, single-masked, 
parallel-group study in patients with CNV secondary to age-relat-
ed macular degeneration. The protocol was conducted in accor-
dance with applicable Good Clinical Practice regulations at 54 sites 
worldwide, and was approved by an institutional review board or 
independent ethics committee at each site. All patients provided 
informed consent prior to participation in the study. The study is 
registered with the trial identifier NCT00511706 at http://clinical-
trials.gov. 
 Eligibility for the study was evaluated at a screening visit. Key 
criteria are listed in  table 1 . If both eyes were eligible for the study, 
the eye with the worse best-corrected visual acuity (BCVA) was 
selected as the study eye. Two patient cohorts were enrolled: those 
with no prior treatment for nvAMD in the study eye (treatment-
naïve cohort) and those with previous treatment for nvAMD (pri-
or treatment cohort). Eyes previously treated with the following 
were excluded: foveal thermal laser or photodynamic treatment of 
nvAMD within 3 months prior to the screening visit; intraocular 
injection of an anti-VEGF treatment within 6 weeks prior to the 
screening visit; intravitreal or periocular corticosteroid treatment 
within 3 months prior to the screening visit; topical corticosteroid 
therapy within 4 weeks prior to the screening visit, or a history of 
intravitreal triamcinolone acetonide injection at doses >4 mg.
 Intervention 
 At the completion of the screening visit (day –28), eligible pa-
tients were treated with ranibizumab 0.5 mg in the study eye. Four 
weeks later, at the baseline study visit (day 0), the need for retreat-
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ment of the study eye was evaluated on optical coherence tomog-
raphy (OCT) and clinical examination. Only patients who demon-
strated at least 1 of the following criteria were eligible for retreat-
ment with ranibizumab: macular cysts; subretinal fluid; pigment 
epithelial detachment (PED); a  ≥ 50-μm increase in the central 
retinal subfield mean thickness from the lowest measurement at 
the previous visit, and new subretinal hemorrhage. Patients were 
also randomized at the baseline visit in a 1: 1 allocation to adjunc-
tive treatment with DEX implant 0.7 mg or sham procedure. Ran-
domization was stratified by cohort, presence or absence of PED, 
and retinal angiomatous proliferation (RAP). Patients and person-
nel conducting the key outcome measure assessments including 
BCVA, OCT, fluorescein angiography (FA), and fundus photog-
raphy (FP) were masked to treatment.
 A single-use applicator with a 22-gauge needle was used to 
place DEX implant in the vitreous cavity through a self-sealing 
scleral oblique/biplanar injection  [34] . For the sham procedure, an 
applicator without a needle or study medication was pressed 
against the conjunctiva and the actuator was depressed, with an 
associated audible click identical to the active treatment. At the 
next study visit (days 7–14), all randomized patients received a 
second protocol-mandated ranibizumab 0.5-mg injection. For pa-
tients who still met the study-defined retreatment criteria, up to 5 
additional ranibizumab treatments were administered during out-
come assessment visits at weeks 5, 9, 13, 17, and 21. At each visit, 
the investigator determined whether the patient qualified for re-
treatment with ranibizumab by satisfying at least 1 of the retreat-
ment criteria. The final outcome assessment visit was at week 25.
 Endpoints 
 The primary efficacy outcome measure was the ranibizumab 
injection-free interval, defined as the time from the second proto-
col-mandated ranibizumab injection (days 7–14 after randomiza-
tion with either DEX or sham) to the determination of eligibility 
to receive the first as-needed ranibizumab injection. Key second-
ary efficacy measures included BCVA in both eyes at each visit, 
central retinal subfield thickness, and foveal center point thickness 
evaluated with OCT in the study eye at each visit, and the areas of 
CNV, leakage from CNV, and the total lesion evaluated with FA 
and FP in the study eye at screening and week 25. BCVA was mea-
sured with the Early Treatment Diabetic Retinopathy Study meth-
od. The OCT measurements of central retinal subfield and foveal 
center point thickness, FAs, and fundus photographs were inde-
pendently analyzed by masked evaluators at a central reading cen-
ter as well as by the investigator. Key safety measures included AEs, 
intraocular pressure (IOP), biomicroscopy, and ophthalmoscopy 
at each visit.
 Sample Size 
 The sample size calculation was based on an estimated ranibi-
zumab injection-free median interval of 60 days in the sham group 
(extrapolated from published data  [43] ) and 122 days in the DEX 
implant group (assuming a between-group difference of 2 months 
to be clinically meaningful). Given these estimates, the expected 
proportion of patients who would not be eligible to receive any 
retreatment of ranibizumab by day 180 was 36% in the DEX im-
plant group and 12.5% in the sham group, with a corresponding 
hazard ratio of 0.492. With a sample size of 90 patients in each co-
hort (45 in each treatment group), a 0.05 level two-sided log rank 
test for equality of survival curves was estimated to provide 80% 
power to detect a difference of this magnitude in the ranibizumab 
injection-free interval. Anticipating a dropout rate of 10%, the 
planned study size was 100 patients in each cohort. 
 Statistical Analyses 
 The analyses of efficacy variables were based on the intent-to-
treat patient population consisting of all randomized patients. 
Safety parameters were evaluated in the population of all random-
 Table 1. Key eligibility criteria for study participation
Inclusion criteria Exclusion criteria
Patients Patients
≥50 years of age
Subfoveal CNV secondary to nvAMD
Required ranibizumab therapy for treatment of nvAMD
Glaucoma
Diabetic retinopathy
Active ocular infection at screening or the baseline visit
History of an increased IOP in response to steroid treatment that 
was ≥10 mm Hg and reached a level of ≥25 mm Hg or that 
required treatment with laser, surgery, or >1 IOP-lowering 
medication
Study eyes
Total size of the lesion ≤12 Macular Photocoagulation Study disc 
areas (30.48 mm2)
Active CNV (classic or occult) representing ≥50% of the area of 
the lesion Study eyes
BCVA of ≥19 and ≤69 letters (approximately 20/40 and 20/400 
on the Snellen scale) using the Early Treatment Diabetic 
Retinopathy Study method
Subfoveal scarring, fibrosis, or atrophy
Retinal pigment epithelium tear that included the fovea
Presence of any causes of CNV other than nvAMD or any other 
ocular disease that could compromise vision
Aphakia or presence of anterior chamber intraocular lens
History of pars plana vitrectomy
Current treatment with ≥2 IOP-lowering medications
Screening or baseline IOP >23 mm Hg if untreated or >21 mm 
Hg if treated with 1 IOP-lowering medication
D
ow
nl
oa
de
d 
by
: 
In
di
an
a 
Un
ive
rs
ity
 - 
Ru
th
 L
illy
 M
ed
ica
l L
ib
ra
ry
   
   
  
19
8.
14
3.
32
.1
 - 
4/
19
/2
01
6 
3:
43
:0
4 
PM
 DEX Implant for Age-Related Macular 
Degeneration 
Ophthalmologica 2015;234:40–54
DOI: 10.1159/000381865
43
ized patients who received DEX implant or sham procedure. Sep-
arate analyses for each cohort were specified in the statistical anal-
ysis plan for the study.
 The ranibizumab injection-free interval was calculated as the 
date of the determination of the eligibility for a third injection (the 
first as-needed injection) minus the date of the second (protocol-
mandated) injection and was analyzed using the Kaplan-Meier 
method. In the analysis, observations for patients who were ineli-
gible for a ranibizumab retreatment prior to week 25, or who dis-
continued the study prior to meeting the eligibility for a third 
 injection, were censored at study exit. The null hypothesis of no 
difference between treatment groups in the cumulative probability 
of requiring ranibizumab retreatment was tested for the overall 
patient population and each cohort using a two-sided log-rank test 
with an alpha level of 0.05. In addition, the ranibizumab injection-
free interval was analyzed using the Cox proportional hazards 
model with treatment and covariates of cohort, presence or ab-
sence of baseline PED, and RAP in the model. The between-group 
difference in the proportion of patients who required no addition-
al injection of ranibizumab was compared using the Cochran-
Mantel-Haenszel test with modified ridit scores stratified by co-
hort and baseline PED and RAP to control for the randomization 
stratification factors of baseline characteristics. In the stratified 
analysis, the treatment effect was examined separately within each 
stratum and then combined for an overall estimate across the stra-
ta. Categorical variables were analyzed using the Pearson χ 2 , Fish-
er’s exact, or Cochran-Mantel-Haenszel test. Continuous variables 
were analyzed using analysis of variance.
 Results 
 A total of 310 patients were screened and received the 
first protocol-mandated ranibizumab injection. At the 
baseline study visit, 67 of these patients either failed to 
meet the retreatment criteria (n = 31) or were ineligible 
for the study due to other reasons (n = 36) such as lesion 
size, BCVA, or significant medical events. The remaining 
243 patients were randomized and received DEX implant 
or sham, followed 1–2 weeks later by the second protocol-
mandated ranibizumab injection ( fig. 1 ).
 There were no significant differences in baseline de-
mographics, study eye characteristics, or ophthalmic 
 history between the treatment groups in either cohort 
 ( table  2 ). However, in the treatment-naïve cohort, the 
mean lesion size of CNV by FA was significantly larger in 
the sham group than in the DEX implant group (7.17 vs. 
5.20 mm 2 , respectively; p = 0.046), and in the prior treat-
ment cohort, the duration of CNV was significantly lon-
ger in the DEX implant group than in the sham group 
(26.6 vs. 19.6 months, respectively; p = 0.034). The most 
commonly used previous treatments for nvAMD in the 
prior treatment cohort were bevacizumab [65.6% (84/128) 
of patients; mean number of injections: 3.8] and ranibizu-
mab [42.2% (54/128) of patients; mean number of injec-
tions: 4.0]. 
 The overall study completion rate was 94.7%; rates 
were high in each treatment group and cohort. The most 
common reasons for early study discontinuation were 
entry criteria for study not met, lost to follow-up, and 
nonocular adverse events unrelated to treatment. None of 
the patients discontinued due to treatment-related ad-
verse events.
 The primary efficacy analysis found that in the overall 
patient population, the ranibizumab injection-free inter-
val was statistically significantly greater in patients treat-
ed with DEX implant than in patients who received the 
sham procedure (p = 0.016;  fig. 2 ). The 50th percentile 
(median) of injection-free survival was 34 days in the 
DEX implant group and 29 days in the sham group; the 
75th percentile of injection-free interval was 85 days (12 
weeks) in the DEX implant group and 56 days (8 weeks) 
in the sham group. In the non-PED subgroup, for DEX 
implant versus sham, the 50th percentile (median) of in-
jection-free interval was 56 versus 34 days, and the 75th 
percentile was 91 versus 68 days, respectively. The differ-
ence in ranibizumab injection-free interval for the PED 
subpopulation was not significant (p = 0.405 for adjunc-
tive therapy vs. ranibizumab alone). 
 The ranibizumab injection-free interval was also ana-
lyzed using the Cox proportional hazards model with 
treatment, PED, and RAP as covariates. Treatment and 
PED were significant predictors with a hazard ratio of 
0.750 (95% CI 0.576, 0.977; p = 0.033) for the DEX im-
plant group versus sham and 1.505 (95% CI 1.151, 1.968; 
p = 0.003) for patients with baseline PED versus other-
wise. Thus, the hazard of requiring the as-needed ranibi-
zumab injection for patients in the DEX implant group 
was only 75% of that for those of the sham group. The 
hazard for patients with baseline PED was 1.5 times more 
than that for patients without baseline PED. The estimat-
ed coefficients for baseline RAP and cohort were not sta-
tistically significant based on this model. 
 Among patients who received the 2 protocol-mandat-
ed injections of ranibizumab, the percentage of patients 
who did not require any as-needed injections was 8.3% 
(10/120) in the DEX implant group and 2.5% (3/118) in 
the sham group (p = 0.048). The mean number of as-
needed ranibizumab injections over the course of the 
study was lower in patients treated with DEX implant 
than in those receiving the sham procedure (3.15 vs. 3.37, 
respectively). In both the treatment-naïve and prior treat-
ment cohorts, as in the overall patient population, the cu-
mulative probability of requiring a third (first as-needed) 
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ranibizumab injection over time was lower in patients 
treated with DEX implant than in patients receiving the 
sham procedure throughout the course of the study. 
However, the difference between treatment groups with-
in each cohort was not statistically significant (p = 0.133 
in the treatment-naïve cohort; p = 0.066 in the prior treat-
ment cohort;  fig. 2 ). 
 There were no statistically significant differences be-
tween treatment groups in the mean change from baseline 
BCVA in the study eye in the overall patient population 
( fig. 3 ). Mean changes from baseline BCVA in the study 
eye during follow-up ranged from +0.3 to +2.2 letters in 
the DEX implant group and from –0.4 to +2.4 letters in 
the group with sham procedure ( table  3 ). In the treat-
ment-naïve cohort, mean changes from baseline BCVA in 
the study eye ranged from +0.3 to +2.7 letters in the DEX 
implant group and from –0.5 to +2.6 letters in the sham 
group; none of the between-group differences were statis-
tically significant. In the prior treatment cohort, mean 
changes from baseline BCVA in the study eye ranged from 
+0.4 to +2.4 letters in the DEX implant group and from 
–0.3 to +2.6 letters in the sham group; none of the be-
tween-group differences were statistically significant in ei-
ther cohort. The distribution of changes from baseline 
BCVA in the study eye was similar between the treatment 
groups at week 25 in the overall patient population ( fig. 4 ). 
Day 0
(randomization) 
Week 1–2 
Week 5
Week 9
Week 13
Week 17
Week 21
Week 25
Treatment-naïve cohort Prior treatment cohort
ScreeningDay –28 First protocol-mandated
ranibizumab injection
Baseline
Only patients who met eligibility for retreatment
with ranibizumab were randomized
Second protocol-mandated
ranibizumab injection
Ranibizumab injection as needed
Final outcome assessment
DEX implant or sham
injection
DEX implant
n = 58
Completed n = 56
Discontinued n = 2
Completed n = 56
Discontinued n = 0
Completed n = 56
Discontinued n = 0
Completed n = 55
Discontinued n = 1
Completed n = 55
Discontinued n = 0
Completed n = 55
Discontinued n = 0
Completed n = 53
                  (91.4%)
Discontinued n = 2
Sham
n = 57
Completed n = 55
Discontinued n = 2
Completed n = 55
Discontinued n = 0
Completed n = 55
Discontinued n = 0
Completed n = 55
Discontinued n = 0
Completed n = 55
Discontinued n = 0
Completed n = 55
Discontinued n = 0
Completed n = 55
                  (96.5%)
Discontinued n = 0
DEX implant
n = 65
Completed n = 65
Discontinued n = 0
Completed n = 65
Discontinued n = 0
Completed n = 63
Discontinued n = 2
Completed n = 63
Discontinued n = 0
Completed n = 63
Discontinued n = 0
Completed n = 63
Discontinued n = 0
Completed n = 62
                  (95.4%)
Discontinued n = 1
Sham
n = 63
Completed n = 63
Discontinued n = 0
Completed n = 63
Discontinued n = 0
Completed n = 63
Discontinued n = 0
Completed n = 62
Discontinued n = 1
Completed n = 62
Discontinued n = 0
Completed n = 61
Discontinued n = 1
Completed n = 60
                  (95.2%)
Discontinued n = 1
 Fig. 1. Patient disposition. Reasons for early discontinuation from the study were nonocular adverse events un-
related to treatment in 3 patients (1 renal failure, 1 myocardial infarction, and 1 liver metastases, pneumonia, and 
myocardial infarction), 3 lost to follow-up, 2 for personal reasons, 1 for protocol violations, and 4 for failure to 
meet baseline study entry criteria. 
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 There were no statistically significant differences be-
tween treatment groups in the percentage of patients with 
at least a 15-letter improvement or worsening in BCVA 
in the study eye in either cohort at any study visit ( ta-
ble 3 ). At week 25, 14.8% (18/122) of patients treated with 
DEX implant and 15.8% (19/120) of patients who re-
ceived the sham procedure had at least a 10-letter im-
provement in BCVA from baseline. 
 The between-group difference in the change from 
baseline foveal center point thickness in the overall pa-
tient population was statistically significant at the study 
visit for the second ranibizumab injection and at week 9, 
favoring the DEX implant group ( fig. 5 ). There were no 
significant between-group differences in improvement in 
central retinal subfield thickness in the overall patient 
population during follow-up.  However, sporadic statisti-
cally significant decreases in mean central retinal subfield 
thickness were seen in patients treated with DEX implant 
(28.8 μm at week 5 and 32.0 μm at week 9; p  ≤ 0.004). 
The areas of CNV, leakage from CNV, and the total le-
sion evaluated with FA in the overall patient population 
decreased significantly from screening to week 25 (p  ≤ 
0.002) in both treatment groups with no statistically sig-
nificant differences between groups ( fig. 6 ).
 Ocular adverse events in the study eye were reported 
for 49.6% (60/121) of patients treated with DEX implant 
and 41.5% (49/118) of those in the sham group (p = 
0.211). None of these adverse events were serious. A high-
er incidence of conjunctival hemorrhage (18.2 vs. 8.5%; 
p = 0.028) and increased IOP (as determined by the in-
vestigator, 13.2 vs. 4.2%; p = 0.014) was reported in pa-
tients treated with DEX implant compared with the sham 
procedure. Cataract-related events were reported in 8 pa-
tients (6.6%) treated with DEX implant and 6 patients 
who received the sham procedure (5.1%; p = 0.615).
 An IOP measurement of  ≥ 25 mm Hg was observed at 
some point in the study for 18.2% (22/121) of the DEX 
implant group compared with 5.1% (6/118) of the sham 
group (p = 0.002), and most of these patients received 
IOP-lowering medications. Findings of IOP  ≥ 25 mm Hg, 
 Table 2. Baseline demographics and clinical characteristics
All patients Treatment-naïve cohort
(no prior nvAMD treatment)
Prior treatment cohort
(prior nvAMD treatment)
DEX implant 
(n = 123)
sham
(n = 120)
DEX implant
(n = 58)
sham
(n = 57)
 DEX impl ant 
(n = 65)
sham
(n = 63)
Age, years 76.1 ± 8.8 (57 – 97) 76.2 ± 8.5 (53 – 94) 77.4 ± 9.5 (57 – 97) 77.4 ± 7.1 (61 – 94) 74.9 ± 8.1 (57 – 94) 75.0 ± 9.5 (53 – 93)
Sex
Male 47 (38.2) 51 (42.5) 21 (36.2) 22 (38.6) 26 (40.0) 29 (46.0)
Female 76 (61.8) 69 (57.5) 37 (63.8) 35 (61.4) 39 (60.0) 34 (54.0)
Race
Caucasian 5 (4.3) 113 (94.2) 52 (89.7) 54 (94.7) 64 (98.5) 59 (93.7)
Asian 5 (4.1) 7 (5.8) 5 (8.6) 3 (5.3) 0 4 (6.3)
Hispanic 2 (1.6) 0 (0) 1 (1.7) 0 1 (1.5) 0
PED
Yes 50 (40.7) 50 (41.7) 20 (34.5) 22 (38.6) 30 (46.2) 28 (44.4)
No 73 (59.3) 70 (58.3) 38 (65.5) 35 (61.4) 35 (53.8) 35 (55.6)
RAP
Yes 4 (3.3) 4 (3.3) 4 (6.9) 3 (5.3) 0 1 (1.6)
No 119 (96.7) 116 (96.7) 54 (93.1) 54 (94.7) 65 (100) 62 (98.4)
Duration of CNV, 
months 16.4 ± 20.4 (1 – 91) 12.3 ± 16.2 (1 – 107) 4.9 ± 10.3 (1 – 68) 4.1 ± 14.0 (1 – 107) 26.6 ± 21.7 (1 – 91) 19.6 ± 14.5 (1 – 61)
Central retinal subfield 
thickness, μm 260.3 ± 123.6 272.5 ± 130.8 262.5 ± 98.9 276.7 ± 133.7 258.3 ± 143.1 268.6 ± 129.2
Foveal thickness, μm 218.0 ± 77.2 222.4 ± 77.3 217.3 ± 63.9 225.4 ± 74.5 218.7 ± 87.7 219.8 ± 80.5
Area of CNV, mm2 9.8 ± 7.7 9.2 ± 6.8 5.2 ± 4.6 7.17 ± 5.39 9.34 ± 7.56 7.82 ± 7.21
Area of CNV leakage, 
mm2 6.8 ± 5.5 7.7 ± 5.3 6.8 ± 5.5 7.69 ± 5.3 9.9 ± 7.6 8.5 ± 7.2
Area of total lesion, 
mm2 9.8 ± 7.7 9.2 ± 6.8 7.3 ± 5.5 9.0 ± 5.96 11.9 ± 8.8 9.4 ± 7.6
BCVA, letters 55.5 ± 15.3 58.1 ± 12.6 55.4 ± 15.5 56.5 ± 13.3 55.5 ± 15.2 59.5 ± 11.9
IOP, mm Hg 14.6 ± 3.0 (7 – 24) 15.2 ± 2.9 (8 – 22) 14.5 ± 3.0 (7 – 24) 15.2 ± 2.8 (10 – 22) 14.8 ± 3.0 (9 – 21) 15.2 ± 3.1 (8 – 22)
Values are presented as mean ± SD (range) or n (%).
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 Fig. 2. Kaplan-Meier survival plot of the time from the second 
(protocol-mandated) dose of ranibizumab to the third (first as-
needed) dose of ranibizumab in patients treated with adjunctive 
dexamethasone intravitreal implant or sham procedure. The cu-
mulative probability of injection-free survival is shown for the 
overall patient population ( a ), the treatment-naïve cohort (pa-
tients with no prior treatment for age-related macular degenera-
tion;  b ), and the prior-treatment cohort (patients previously treat-
ed for age-related macular degeneration;  c ). The between-group 
difference in injection-free survival in the overall study population 
was statistically significant (p = 0.016). 
(For figure 2c see next page.)
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as well as findings of an increase in IOP from baseline of 
 ≥ 10 mm Hg, peaked at week 9 in the DEX implant group 
(12.2% of patients for both findings). Only 1 patient 
(0.8%) had IOP >35 mm Hg at week 9. Among patients 
with no history of IOP medication use at baseline, 13.0% 
(15/115) in the DEX implant group, and 4.2% (5/118) in 
the sham group initiated IOP-lowering medication dur-
ing the study. No surgeries were required to control IOP 
in any patients in the study. There were no statistically 
significant differences between treatment groups in the 
occurrence of IOP  ≥ 25 mm Hg or increases in IOP from 
baseline of  ≥ 10 mm Hg after week 9. At week 25, 1 patient 
(0.9%) in the DEX implant group and 2 patients (1.8%) in 
the sham group had IOP  ≥ 25 mm Hg.
 There were no significant differences between treat-
ment groups in changes from baseline biomicroscopy 
and ophthalmoscopy findings in the study eye in the 
overall patient population, with the exception of con-
junctival hemorrhage. Although reported in >2% of pa-
tients in each treatment group, the frequency of this find-
ing was not statistically significantly different between 
groups.
 Discussion 
 Although intravitreal anti-VEGF therapy is currently 
the most effective treatment for nvAMD, it is not effective 
in all patients, and frequent injections, usually monthly, 
are required to maintain its therapeutic benefit  [44] . In 
the Comparison of Age-Related Macular Degeneration 
Treatments Trial at 1 year, 56% of patients who received 
ranibizumab monthly had fluid on OCT  [45] . Inflam-
mation represents another potential target of therapy 
in nvAMD, which could be approached with cortico-
steroids. Combination treatment using therapies with 
different mechanisms of action may allow a reduced fre-
quency of intravitreal injections and improve long-term 
efficacy, safety, and outcomes  [7, 8, 11–13] . In this study, 
adjunctive treatment with DEX implant significantly de-
layed the first as-needed injection of ranibizumab and 
significantly reduced the need for repeated ranibizumab 
treatment in patients with CNV secondary to nvAMD. 
The number of patients requiring no additional injec-
tions of ranibizumab was higher in the DEX implant 
group than in the sham group. Patients in the DEX im-
plant group, however, had an additional scheduled intra-
vitreal injection for implant placement, which in clinical 
practice can be reduced by performing both treatments 
on the same day. Visual outcomes and decreases in CNV 
size and leakage were as favorable in patients treated with 
adjunctive DEX implant as ranibizumab alone, despite 
the reduced frequency of ranibizumab injections. Statisti-
cally significant improvements in central retinal subfield 
thickness were seen only in patients treated with the com-
bination therapy (DEX implant and ranibizumab). Ad-
ditionally, there was a clear decrease in leakage area in the 
prior treatment group who received DEX.
 Approximately 50% of patients in the treatment-naïve 
cohort and 60% of patients in the prior treatment cohort 
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There were no statistically significant dif-
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for nvAMD required the first as-needed ranibizumab in-
jection at week 5 (4 weeks after the second injection), re-
gardless of whether they had received the DEX implant or 
the sham procedure. However, after week 5, the cumu-
lative probability of requiring a third (first as-needed) ra-
nibizumab injection over time was lower in patients treat-
ed with DEX implant than in patients receiving the sham 
procedure. Although the differences between treatment 
groups for the time to the first as-needed injection of 
 ranibizumab within each cohort were not statistically sig-
nificant, the difference between treatment groups is sta-
tistically significant in the overall patient population.
 Patients in this study required retreatment after an ini-
tial ranibizumab injection due to continued  edema, PED, 
or new subretinal hemorrhage. Thus, the study popula-
tion consisted of patients who did not respond adequate-
ly to a single ranibizumab injection and may have includ-
ed patients with loosely controlled VEGF that is difficult 
to treat even with multiple injections. Only one third of 
the patients in the study had gained at least 2 lines in 
BCVA from screening at the end of the study, after an av-
erage of 5 ranibizumab injections. The patients respond-
ed favorably to DEX implant; DEX implant treatment 
 reduced central foveal thickness in the study population 
compared with the sham procedure. However, few pa-
tients demonstrated a sustained, clinically significant im-
provement in BCVA from baseline in either treatment 
group.
 The injections of DEX implant were well tolerated. 
Increased IOP is a well-described side effect of intravit-
real corticosteroid treatment  [46, 47] , and in this study 
an IOP  ≥ 25 mm Hg occurred in 18.2% of patients treat-
ed with DEX implant. In all cases, the IOP was subse-
quently controlled with IOP-lowering eye drops; no laser 
or surgical intervention was required. The only other ad-
verse event that was more common in the DEX implant 
group than in the sham group was conjunctival hemor-
rhage.
 Intravitreal injections of anti-VEGF have generally 
been associated with fewer ocular complications than in-
travitreal corticosteroid injections. However, monthly 
treatment with ranibizumab may be associated with an 
increased risk of cerebrovascular incidents  [48, 49] . Thus, 
the use of an adjunctive treatment (e.g. DEX implant) that 
would allow reduced frequency of ranibizumab injections 
may be associated with improved safety in large patient 
populations. As inflammatory cells associated with CNV 
tissue may induce CNV and stimulate other pathologic 
processes, such as fibrosis, that lead to vision loss in 
nvAMD  [8–10] , immunologic effects of high initial ste-
roid concentrations following DEX implant administra-
tion, such as leukocyte apoptosis  [22–24, 50] , may ac-
count for the beneficial effect of DEX implant observed 
in this study.
 A potential limitation of this study involves how inves-
tigators were masked. Although OCT, FA, and FP results 
were evaluated by masked readers at a central reading 
center, the investigators who determined study eligibility 
and the need for retreatment were not masked with re-
spect to treatment assignment. Also, a single injection of 
DEX implant was given with a 6-month follow-up. Sub-
sequent studies in patients with retinal vein occlusion in-
dicate that DEX may be efficacious for approximately 3–4 
months from implant  [40, 51] . Taking into account that 
the mean duration of the effectiveness of DEX implant 
varies between 4 and 6 months, it would have been valu-
able to know whether the statistically significant increase 
in the time interval before the first as-needed injection 
was also prolonged over the following injections, but this 
was beyond the original scope of the study. Finally, the 
study sample size may have been too small as it was based 
on an estimated ranibizumab injection-free median in-
terval of 122 days in the DEX implant group and 60 days 
in the sham group.
 In summary, the results of this pilot proof-of-concept 
study demonstrate that DEX implant has the potential to 
influence the administration regimen of ranibizumab in 
nvAMD patients. Combination treatment with DEX im-
plant and ranibizumab provided the same efficacy and 
allowed a statistically significant, though modest, reduc-
tion in the frequency of ranibizumab injections com-
pared with ranibizumab used alone. DEX implant may 
also prove to be useful in combination with other treat-
ments for nvAMD. Additional studies will be needed to 
further define the role of DEX implant and develop new 
algorithms for the treatment of neovascular ocular dis-
ease.
 Conclusion 
 In a 6-month single-masked, randomized, sham-con-
trolled study, patients with nvAMD received intravitreal 
ranibizumab 0.5 mg, followed 4 weeks later with DEX im-
plant 0.7 mg or sham procedure. The implant modestly 
delayed and reduced the need for repeated ranibizumab 
treatment, and had an acceptable safety profile.
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